Abstract
The management of intraperitoneal tumors, especially when confined to the peritoneal cavity and/or associated with malignant ascites, requires the use of intraperitoneal (i.p.) cisplatin-based chemotherapy. This therapeutic approach, enabling high concentrations of drug and long duration of tumor tissue exposure, while generating a systemic exposure similar to that obtained with intravenous (i.v.) infusion, significantly improves therapeutic ratio. Nowadays, as feasibility issues are easy to overcome, intraperitoneal chemotherapy provides a safe, effective treatment for the management of peritoneal disease, particularly ovarian carcinoma. In this paper we review pharmacological issues of intraperitoneal cispiatin-based chemotherapy in order to provide a ready to use information collection for clinical practice and ongoing research.
Original language | English |
---|---|
Pages (from-to) | 23-25 |
Number of pages | 3 |
Journal | Journal of Chemotherapy |
Volume | 16 |
Issue number | SUPPL. 5 |
Publication status | Published - Nov 2004 |
Keywords
- Cisplatin
- Clinical pharmacology
- Intraperitoneal chemotherapy
ASJC Scopus subject areas
- Microbiology (medical)
- Pharmacology (medical)